One year after the start of the project and we finally had our first in-person meeting. On 15th and 16th November 2021, the EU-funded MARVEL project team has met at the MARVEL M12 meeting organized by the SCITEC-CNR partner in Milan, Italy. During the meeting, we highlight the achievements of the first 12 months of the project and discussed our next steps and upcoming activities.

On the one hand, the first year was dedicated to the analysis of technical requirements and specifications as well as the selection of the criteria for the system demonstration. In addition to this, specific attention was given to the biological sample’s parameters, their selection, and processing. On the other hand, a strong focus was on the development of new affinity peptide ligands that outclass antibody-based isolation methods in terms of capturing efficiency, versatility, and cost-effectiveness. These achieved targets will introduce a breakthrough in current EV isolation standards.

The next year will be mostly focused on the integration and optimization of the developed technology into several systems, leading to ground-breaking innovations for EV deployment in cardiac repair and the non-invasive diagnosis of bladder cancer.